BTG2 and prostate carcinoma: Our results showed that the expression levels of SEMA3B and BTG2 in the TSPX-high prostate cancer samples were similar with those in the non-tumor prostate samples (P-value > 0.05), while those in TSPX-low prostate cancer samples were significantly low (Figure 5G).